| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | AHH; AHRR; CP11; CYP1; P1-450; P450-C; P450DX |
| Entrez GeneID | 1543 |
| clone | 6G5 |
| WB Predicted band size | 58kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CYP1A1 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CRKL抗体的3篇示例参考文献(内容为虚构概括，建议通过PubMed或学术数据库查询真实文献)：
---
1. **Title**: "CRKL as a critical signaling adaptor in BCR-ABL-driven leukemogenesis"
**Authors**: Senechal, K., et al.
**Summary**: 本研究利用CRKL特异性抗体，揭示了CRKL在BCR-ABL阳性白血病中通过调控RAS-MAPK和PI3K/AKT信号通路促进细胞增殖和存活的机制。实验表明，抑制CRKL可显著降低白血病细胞系的恶性表型。
2. **Title**: "CRKL antibody-based targeting disrupts tumor metastasis in solid cancers"
**Authors**: Huang, X., et al.
**Summary**: 通过开发高特异性CRKL单克隆抗体，研究者证明其在乳腺癌和肺癌模型中可阻断CRKL与下游效应分子(如C3G)的相互作用，抑制肿瘤细胞的迁移和侵袭，为实体瘤治疗提供了潜在策略。
3. **Title**: "CRKL modulates host-pathogen interactions in HIV-1 infection"
**Authors**: Sakamoto, Y., et al.
**Summary**: 该文献报道了CRKL抗体在HIV-1感染研究中的应用，发现CRKL通过与病毒蛋白Nef结合介导免疫逃逸。阻断CRKL功能可增强宿主T细胞的抗病毒反应，为抗逆转录病毒治疗提供新思路。
---
如需真实文献，建议检索PubMed(https://pubmed.ncbi.nlm.nih.gov)并搜索关键词“CRKL antibody”或“CRKL signaling”，筛选近年高被引论文。
CRKL (CT10-regulated kinase-like) antibody is a key reagent used to detect the CRKL protein, an adaptor molecule involved in diverse cellular signaling pathways. CRKL belongs to the Crk protein family, characterized by SH2 and SH3 domains that mediate protein-protein interactions. It plays a critical role in transmitting signals from tyrosine kinases, including BCR-ABL in chronic myeloid leukemia (CML), by linking phosphorylated receptors or cytoplasmic kinases to downstream effectors like RAS-MAPK, PI3K/AKT, and JNK pathways. This regulates processes such as cell proliferation, adhesion, migration, and apoptosis.
CRKL gained attention due to its overexpression in cancers, particularly CML, where it localizes to the Philadelphia (Ph) chromosome-derived BCR-ABL fusion protein. Its involvement in oncogenic signaling makes it a potential therapeutic target. CRKL antibodies are widely utilized in research to study cancer mechanisms, monitor BCR-ABL activity, or assess drug resistance. They are employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to quantify CRKL expression, phosphorylation status, or subcellular localization.
Commercially available CRKL antibodies are typically validated for specificity against human or mouse isoforms. However, variations in antibody performance across applications necessitate careful validation. Understanding CRKL's role in disease continues to drive the development and application of these antibodies in both basic research and clinical diagnostics.
×
